Related Experiment Video
Updated: Jun 6, 2025
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
TMEM35B as a novel biomarker for diagnosing gliomas
Gongbo Liang1, Xuwen Lai1, Guangning Yan1
1Department of Pathology, General Hospital of Southern Theater Command, Guangzhou, R.P. China.
Aims:
There is little information about transmembrane protein 35B (TMEM35B) expression in glioma, and its functions in glioma remains no clue.
Patients & Methods:
Immunohistochemistry was used to measure TMEM35B expression levels and CCK8 and Transwell assays were analyzed the proliferative and migratory and invasive.
Results:
TMEM35B protein was significantly higher in gliomas and correlated with a higher tumor TNM stages. Receiver operating characteristic curve analysis revealed that TMEM35B had high diagnostic value in distinguishing among glioma, normal tissues, tumor stages III+IV, and I+II. Additionally, TMEM35B knockdown inhibited the proliferative, migratory, and invasive capacities of glioma cells.
Conclusions:
TMEM35B expression is upregulated in gliomas, and its knockdown hinders tumor progression, highlighting the protein as a potential biomarker for glioma diagnosis.
